drugset
drugset / Trial / NCT00866476

Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection: Phase IIa

NCT00866476 ↗

Phase 2 Terminated 20 enrolled University of Maryland, Baltimore PATH · collab
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to determine whether CVD 1208S (a live, attenuated, oral vaccine) is safe and effective in the prevention of Shigella infection.

Timeline

Start
2010-01
Primary completion
2010-02
Completion
2010-02

Outcome

Outcome not reported

Stopped: “Reactogenicity met study halting criteria”

Drugs

EvaluationDrugModalityDoseRoute
Subject CVD 1208S Vaccine 1e+09 unknown Oral

Indications

shigellosis